臨床外科79巻7号

2024年07月発行

特集 外科医が知っておくべき 肝胆膵腫瘍に対する薬物療法 胆道・膵臓

膵原発神経内分泌腫瘍に対する薬物療法

著者： 青木琢¹

所属機関： ¹獨協医科大学肝・胆・膵外科

ページ範囲：P.786 - P.790

【ポイント】
◆膵高分化型神経内分泌腫瘍（NET）に対する薬物療法として，ソマトスタチンアナログ，分子標的薬，細胞傷害性抗癌薬が用いられている．各療法にはエビデンスがあるが，直接比較のデータは乏しく，使い分けをアルゴリズムで示すにはデータが乏しい．
◆非常に有効な放射線内用療法であるPRRTがわが国にも導入され，早期治療のエビデンスも出たことで，今後薬物療法の戦略が一変する可能性がある．
◆薬物療法の進歩に伴い，切除不能進行膵NET治療における外科治療の役割も変化が予想される．

参考文献

1）Llyod RV, Osamura RY, Klöppel G, et al（eds）；WHO classification of tumours of endocrine organs, 4th edition. IRAC, Lyon, 2017

2）Ohmoto A, Rokutan H, Yachida S：Pancreatic neuroendocrine neoplasms：basic biology, current treatment strategies and prospects for the future. Int J Mol Sci 18：143, 2017

3）Caplin ME, Pavel M, Ćwikla JB, et al：Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371：224-233, 2014

4）Caplin ME, Pavel M, Phan AT, et al：Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours：final results of the CLARINET open-label extension study. Endocrine 71：502-513, 2021

5）Ito T, Honma Y, Hijioka S, et al：Phase Ⅱ study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. Invest New Drugs 35：499-508, 2017

6）Xu J, Shen L, Bai C, et al：Surufatinib in advanced pancreatic neuroendocrine tumours（SANET-p）：a randomized, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21：1489-1399, 2020

7）Dasari A, Hamilton EP, Falchook GS, et a l：A doseescalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, ＆ 3, FGFR 1, and CSF 1R, in US patients with neuroendocrine tumors. Invest New Drugs 41：421-430, 2023

8）Yao JC, Shah MH, Ito T, et al：Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364：514-523, 2011

9）Raymond E, Dahan L, Raoul JL, et al：Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364：501-513, 2011

10）Moertel CG, Lefkopoulo M, Lipsitz S, et al：Streptozocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326：519-523, 1992

11）Aoki T, Kokudo N, Komoto I, et al：Streptozocin chemotherapy for advanced/metastatic wel-differentiated neuroendocrine tumors：an analysis of a multi-center survey in Japan. J Gastroenterol 50：769-775, 2015

12）Komoto I, Kokudo N, Aoki T, et al：Phase Ⅰ/Ⅱ study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. Jpn J Clin Oncol 52：716-724, 2022

13）Kunz PL, Graham NT, Catalano PJ, et al：Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors（ECOG-ACRIN E2211）. J Clin Oncol 41：1359-1369, 2023

Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376：125-135, 2017

Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours（NETTER-1）：final overall survival and long-term safety results from a open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22：1752-1763, 2021

Lu-DOTATATE for neiroendocrine tumors in phase 1/2 prospective Japanese trial. J Hepatobiliary Pancreat Sci 29：487-499, 2022

17）Ikeda M, Morizane C, Hijioka S, et al：Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. Pancreatology 20：944-950, 2020

18）Pavel M, Öberg K, Falconi M, et al：Gastroenteropancreatic neuroendocrine neoplasms：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31：844-860, 2020

19）National Comprehensive Cancer Network. 〔https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf〕（2024年3月29日アクセス）